Clinical Trial Detail

NCT ID NCT04272203
Title Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AbbVie
Indications

lung non-small cell carcinoma

acute myeloid leukemia

Therapies

ABBV-184

Age Groups: adult senior

No variant requirements are available.